Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of November 2021, with a filing date of November 12, 2021. The document serves as a notice to shareholders regarding the scheduling of the Company's Annual General Meeting.
Key Event
The Company has scheduled its Annual General Meeting of Shareholders for December 27, 2021, at 4:00 p.m. Israel time. The meeting will be held at the offices of Gross & Co., One Azrieli Center, Tel Aviv, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural notice and does not contain financial statements or performance data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document solely announces the upcoming shareholder meeting.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It includes an exhibit (99.1) containing the formal Notice of the Annual General Meeting, which is incorporated by reference into the Company's Form F-3 and Form S-8 registration statements.
Investor Verification Checklist
- Verify the correct registrant name is BiondVax Pharmaceuticals Ltd., not Scinai Immunotherapeutics Ltd.
- Confirm the date, time, and location of the Annual General Meeting scheduled for December 27, 2021.
- Review the attached Exhibit 99.1 for specific agenda items and voting procedures for the shareholder meeting.
- Note that this filing does not contain updated financial results; refer to recent Form 20-F or 8-K filings for financial data.